Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
2 Wonderful Dividends At Bargain Basement Prices
Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical avera...
Boomers Are Grabbing These Big Beautiful Blue-Chip Dividend Giants For Decades of Passive Income
Blue-chip dividend stocks are shares of large, well-established, financially stable companies with a consistent and reliable performance history.
Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)
Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with B...
5 of the Safest Strong-Buy High-Yield Dividend Stocks Are On Sale Now
Investors love dividend stocks, especially high-yield ones, because they offer a significant income stream and have substantial total return potential.
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's C...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Abecma--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels.
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note
Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Bristol Myers Squibb (BMY) settling at $49, representing a +1.22% change from its previous close.
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific ...
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Related Companies